

Global burden of acute lower respiratory infection associated with human parainfluenza virus in children younger than 5 years for 2018: a systematic review and meta-analysis



Xin Wang, You Li, Maria Deloria-Knoll, Shabir A Madhi, Cheryl Cohen, Vina Lea Arguelles*, Sudha Basnet*, Quique Bassat*, W Abdullah Brooks*, Marcela Echavarría*, Rodrigo A Fasce*, Angela Gentile, Doli Goswami*, Nusrat Homaira*, Stephen R C Howie*, Karen L Kotloff*, Najwa Khuri-Bulos*, Anand Krishnan*, Marilla G Lucero*, Socorro Lupisan*, Maria Mathisen*, Kenneth A McLean*, Ainara Mira-Iglesias*, Cinta Moraleda*, Michiko Okamoto*, Hideo Oshitani*, Katherine L O'Brien*, Betty E Owor*, Zeba A Rasmussen*, Barbara A Rath*, Vahid Salimi*, Pongpun Sawatwong*, J Anthony G Scott*, Eric A F Simões*, Viviana Sotomayor*, Donald M Thea*, Florette K Treurnicht*, Lay-Myint Yoshida*, Heather J Zar*, Harry Campbell, Harish Nair, for the Respiratory Virus Global Epidemiology Network



Summary

Background Human parainfluenza virus (hPIV) is a common virus in childhood acute lower respiratory infections (ALRI). However, no estimates have been made to quantify the global burden of hPIV in childhood ALRI. We aimed to estimate the global and regional hPIV-associated and hPIV-attributable ALRI incidence, hospital admissions, and mortality for children younger than 5 years and stratified by 0–5 months, 6–11 months, and 12–59 months of age.

Methods We did a systematic review of hPIV-associated ALRI burden studies published between Jan 1, 1995, and Dec 31, 2020, found in MEDLINE, Embase, Global Health, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Global Health Library, three Chinese databases, and Google search, and also identified a further 41 high-quality unpublished studies through an international research network. We included studies reporting community incidence of ALRI with laboratory-confirmed hPIV; hospital admission rates of ALRI or ALRI with hypoxaemia in children with laboratory-confirmed hPIV; proportions of patients with ALRI admitted to hospital with laboratory-confirmed hPIV; or in-hospital case–fatality ratios (hCFRs) of ALRI with laboratory-confirmed hPIV. We used a modified Newcastle-Ottawa Scale to assess risk of bias. We analysed incidence, hospital admission rates, and hCFRs of hPIV-associated ALRI using a generalised linear mixed model. Adjustment was made to account for the non-detection of hPIV-4. We estimated hPIV-associated ALRI cases, hospital admissions, and in-hospital deaths using adjusted incidence, hospital admission rates, and hCFRs. We estimated the overall hPIV-associated ALRI mortality (both in-hospital and out-hospital mortality) on the basis of the number of in-hospital deaths and care-seeking for child pneumonia. We estimated hPIV-attributable ALRI burden by accounting for attributable fractions for hPIV in laboratory-confirmed hPIV cases and deaths. Sensitivity analyses were done to validate the estimates of overall hPIV-associated ALRI mortality and hPIV-attributable ALRI mortality. The systematic review protocol was registered on PROSPERO (CRD42019148570).

Findings 203 studies were identified, including 162 hPIV-associated ALRI burden studies and a further 41 high-quality unpublished studies. Globally in 2018, an estimated 18·8 million (uncertainty range 12·8–28·9) ALRI cases, 725 000 (433 000–1 260 000) ALRI hospital admissions, and 34 400 (16 400–73 800) ALRI deaths were attributable to hPIVs among children younger than 5 years. The age-stratified and region-stratified analyses suggested that about 61% (35% for infants aged 0–5 months and 26% for 6–11 months) of the hospital admissions and 66% (42% for infants aged 0–5 months and 24% for 6–11 months) of the in-hospital deaths were in infants, and 70% of the in-hospital deaths were in low-income and lower-middle-income countries. Between 73% and 100% (varying by outcome) of the data had a low risk in study design; the proportion was 46–65% for the adjustment for health-care use, 59–77% for patient groups excluded, 54–93% for case definition, 42–93% for sampling strategy, and 67–77% for test methods. Heterogeneity in estimates was found between studies for each outcome.

Interpretation We report the first global burden estimates of hPIV-associated and hPIV-attributable ALRI in young children. Globally, approximately 13% of ALRI cases, 4–14% of ALRI hospital admissions, and 4% of childhood ALRI mortality were attributable to hPIV. These numbers indicate a potentially notable burden of hPIV in ALRI morbidity and mortality in young children. These estimates should encourage and inform investment to accelerate the development of targeted interventions.

Funding Bill & Melinda Gates Foundation.

Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Lancet Glob Health 2021; 9: e1077–87

Published Online

June 21, 2021

[https://doi.org/10.1016/S2214-109X\(21\)00218-7](https://doi.org/10.1016/S2214-109X(21)00218-7)

S2214-109X(21)00218-7

See [Comment](#) page e1033

*Authors listed alphabetically

Centre for Global Health, Usher Institute, Edinburgh Medical School, University of

Edinburgh, Edinburgh, UK

(X Wang PhD, Y Li PhD,

K A McLean MBChB,

Prof H Campbell MD,

Prof H Nair PhD); Department

of International Health,

International Vaccine Access

Center, Johns Hopkins

Bloomberg School of Public

Health, Baltimore, MD, USA

(M Deloria-Knoll PhD,

W A Brooks MD,

Prof K L O'Brien MD);

South African Medical Research

Council, Vaccines and

Infectious Diseases Analytical

Research Unit, Soweto, South

Africa (Prof S A Madhi PhD);

Department of Science and

Technology, National Research

Foundation, Vaccine

Preventable Diseases, Faculty

of Health Sciences, University

of the Witwatersrand,

Johannesburg, South Africa

(Prof S A Madhi); Centre for

Respiratory Disease and

Meningitis, National Institute

for Communicable Diseases,

Johannesburg, South Africa

(C Cohen MD); School of Public

Health, Faculty of Health

Sciences, University of the

Witwatersrand, Johannesburg,

South Africa (C Cohen);

Research Institute for Tropical

Medicine, Muntinlupa, Metro

Manila, Philippines

(V L Arguelles MPH);

Department of Child Health,

Tribhuvan University,

Katmandu, Nepal (Prof S Basnet MD); the Centre for International Health, University of Bergen, Bergen, Norway (Prof S Basnet); Barcelona Global Health Institute, Hospital Clínic-University of Barcelona, Barcelona, Spain (Prof Q Bassat MD); Centro de Investigación em Saúde de Manhiça, Maputo, Mozambique (Prof Q Bassat); Institutió Catalana de Recerca i Estudis Avançats, Barcelona, Spain (Prof Q Bassat); Paediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain (Prof Q Bassat); Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain (Prof Q Bassat); Clinical Virology Unit, Centro de Educación Médica e Investigaciones Clínicas, Argentina (M Echavarría PhD); Public Health Institute of Chile, Región Metropolitana, Chile (R A Fasce BSc); Ricardo Gutiérrez Children Hospital, Buenos Aires, Argentina (Prof A Gentile MD); International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh (D Goswami MSc, N Homaira PhD); Discipline of Paediatrics, School of Women's and Children's Health, The University of New South Wales, Sydney, NSW, Australia (N Homaira); Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, London, UK (S R C Howie PhD); Department of Paediatrics, Child & Youth Health, University of Auckland, Auckland, New Zealand (S R C Howie); Department of Pediatrics and Department of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA (Prof K L Kotloff MD); Department of Pediatrics, University of Jordan, School of Medicine, Amman, Jordan (Prof N Khuri-Bulos MD); Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India (Prof A Krishnan MD); Research Institute for Tropical Medicine, Muntinlupa, Philippines (M G Lucero MD, S Lupisan MD);

Research in context

Evidence before this study

Human parainfluenza virus (hPIV), including four major serotypes, is commonly detected in childhood acute lower respiratory infections (ALRI). Results from multi-country pneumonia case-control studies show that hPIV is one of the leading causative viruses of childhood ALRI. Two meta-analyses estimated that hPIV could be detected in 2.7–5.8% of children younger than 5 years admitted to hospital for ALRI.

The estimates were either developed on the basis of a small number of studies or for a specific country. No estimates have been made to quantify the global burden of ALRI because of hPIV among children younger than 5 years, or by narrow age bands. We searched PubMed for studies published between Jan 1, 1995, and May 25, 2021, which reported the global burden of hPIV, using the search terms “(parainfluenza OR PIV) AND (global) AND (child OR infant)”.

Added value of this study

We did a systematic review of 203 studies with data on hPIV-associated ALRI community incidence rates, hospital admission rates, proportion of laboratory-confirmed hPIV among ALRI cases admitted to hospital, and in-hospital

case-fatality ratios, including 41 high-quality unpublished studies that provided data by narrow age bands among children younger than 5 years, and 45 studies from low-income and lower middle-income countries. We estimated that, in 2018, approximately 18.8 million (uncertainty range [UR] 12.8–28.9) ALRI cases, 725 000 (UR 433 000–1 260 000) ALRI hospital admissions, and 34 400 (UR 16 400–73 800) ALRI deaths were attributable to hPIV globally among children younger than 5 years. When analysed in the context of all-cause ALRI burden estimates, hPIV accounts for 13% of ALRI cases, 4–14% of ALRI hospital admissions, and 4% of ALRI mortality. Similar to other respiratory viruses, a larger proportion of hPIV hospital admissions (61%) and in-hospital deaths (66%) occurred in infants younger than 1 year.

Implications of all the available evidence

Our systematic review provides the first global burden estimates of hPIV-associated and hPIV-attributable ALRI among children younger than 5 years, and estimates by narrow age groups. These burden estimates show the role of hPIV in causing child ALRI morbidity and mortality, and should inform investment to accelerate the development of targeted interventions.

Introduction

Acute lower respiratory infection (ALRI) is one of the leading causes of morbidity and mortality in children globally, accounting for 10% of mortality in children younger than 5 years in 2017.¹ Human parainfluenza virus (hPIV), primarily from four major serotypes (hPIV-1 to hPIV-4), usually causes epidemics in the spring and early summer. hPIV can cause ALRI and more severe infections in young children, leading to a considerable disease burden.^{2,3}

Previous systematic reviews have estimated that hPIV could be detected in 2.7–5.8% of ALRI cases in children younger than 5 years, but the estimates were either developed on the basis of a small number of studies or for the population of only one country.^{4,5} Results from pooled analyses have shown evidence for the causal attribution of hPIV, and estimated that 43–87% of ALRI cases with laboratory-confirmed hPIV in children younger than 5 years are attributable to hPIV.^{6,7} There are no licensed hPIV vaccines or antiviral treatments.⁸ A few hPIV-3 candidate vaccines are under development, and have been assessed in phase 1 and 2 trials showing safety and immunogenicity in seronegative children older than 6 months.^{9–11} hPIV-1 and hPIV-2 candidate vaccines are also under development.^{12–14}

Estimates have not been made to quantify the global burden of hPIV in children younger than 5 years. Thus, we estimated the global and regional number of hPIV-associated ALRI cases, hospital admissions, and deaths by age bands (ie, 0–5 months, 6–11 months, and 12–59 months) among children younger than 5 years

for 2018. We also estimated the global burden of ALRI that is attributable to hPIV by accounting for the causal attribution of hPIV. These estimates could help to identify age groups that are at a high risk of severe hPIV respiratory infections, and guide health investment priorities, resource allocation, and development of targeted pharmaceutical and non-pharmaceutical intervention strategies.

Methods

Systematic review, definitions, and assessment of risk of bias

We did a systematic review of hPIV-associated ALRI burden in children younger than 5 years (appendix pp 5, 6). We searched MEDLINE, Embase, Global Health, Cumulative Index to Nursing and Allied Health Literature, Web of Science, Global Health Library, three Chinese databases (China National Knowledge Infrastructure, Wanfang, and Chongqing VIP), and Google search (for grey literature) for studies published between Jan 1, 1995, and Dec 31, 2020. We also contacted authors who might have relevant data, especially incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFR) data. Several of these authors agreed to share more detailed and recent data (we included these in the research network). We used the terms and related words “parainfluenza virus” AND “acute lower respiratory infections” AND “burden” AND “children”. No language or publication restrictions were applied (languages other than English or Chinese were translated with Google translate), and three reviewers

(XW, YL, and KAM) screened the titles and abstracts for eligibility. For potentially eligible studies, reviewers screened full-text articles for final inclusion, and extracted eligible data independently. Disagreements were resolved by discussion between reviewers. For datasets that overlapped in study population, location, and period, we included either the more detailed dataset (eg, stratified by finer age groups) or the more recent version. We supplemented the data from published studies with additional high-quality unpublished data (from ongoing studies or the re-analysis of previously published studies) using agreed standard approaches and definitions within the Respiratory Virus Global Epidemiology Network.¹⁵

We reported any of these data for children younger than 5 years: community incidence of ALRI (clinical pneumonia, according to the 2005 WHO Integrated Management of Childhood Illnesses)¹⁶ with laboratory-confirmed hPIV (ie, molecular test, culture, and antigen detection test); hospital admission rates of ALRI (a physician-confirmed diagnosis of ALRI) or ALRI with hypoxaemia in children with laboratory-confirmed hPIV; proportion of laboratory-confirmed hPIV among ALRI cases admitted to hospital; or hCFRs of ALRI with laboratory-confirmed hPIV. Details of case definitions are in the appendix (pp 3, 4).

Studies had to use a clear case definition for specimen collection and testing, and studies that reported incidence and hospital admission rate data had to show data for at least 1 complete calendar year (or at least one full season if in a temperate region with defined hPIV seasons). We included hCFR data for any length of study period. We included data on the proportion of hPIV positives if they were from at least 1 full calendar year. We excluded studies without a clear denominator population at risk (limited to those reporting incidence and hospital admission rate data), those in which hPIV was detected only in samples that were tested negative for other viruses, those which reported modelled burden estimates, those in which hPIV infections were diagnosed on the basis of serology alone, or those which only included population subgroups with high-risk conditions.

The risk of bias in included studies was assessed using a modified Newcastle-Ottawa Scale, containing seven domains: study design, adjustment for health-care use, patient groups excluded, case definition, sampling strategy, diagnostic testing, and hypoxaemia ascertainment (appendix pp 30, 31).¹⁷

Statistical analysis

Our approach to burden estimation, including main analyses and sensitivity analyses, is summarised in the appendix (p 9). We estimated hPIV-associated ALRI cases, hospital admissions, and in-hospital deaths using a strategy similar to our previous analysis.¹⁵ We pooled incidence rates, hospital admission rates, and hCFRs of hPIV-associated ALRI using a generalised linear mixed

model.¹⁸ Differences between studies were anticipated, thus we used the generalised linear mixed model that accounts for the differences. Before meta-analysis, for the incidence rate and hospital admission rate, we scaled the population-at-risk for the level of testing per study where available before meta-analyses (appendix p 28). Not all studies reported data for hPIV-4, so we adjusted the hPIV case number to account for missing hPIV-4 cases in incidence and hospital admission rates and proportion positives on the basis of an estimated proportion of hPIV-4 in all hPIV cases (12% based on 24 studies; appendix p 17). Similarly, we adjusted hCFR estimates to account for missing hPIV-4 hospital admissions and deaths on the basis of estimated proportion and hCFRs of four hPIV types (appendix p 18).

After meta-analyses, we chose the Monte Carlo Simulation to estimate morbidity burden because it allows us to combine meta-estimates and population estimates (UN population estimates for 2018).¹⁹ The median value of 10 000 samples simulated from a log-normal distribution was used as the point burden estimate and the 2.5th and 97.5th percentiles as the 95% uncertainty range (UR). In the main analysis, we reported estimates stratified by three non-overlapping age bands (0–5 months, 6–11 months, and 12–59 months) and by 2018 child mortality settings (low or high, with a cut-off point of the median value of the mortality rate of those younger than 5 years) for each outcome where available.²⁰ The global results were calculated as the sum of age-specific and region-specific estimates. The numbers of cases were rounded to the nearest thousand and the number of deaths to the nearest hundred. In community settings, we reported the incidence for the overall age band (0–59 months) because data were insufficient to allow disaggregation by narrower age bands. We imputed the numbers of cases for 0–59 months using a multiple imputation approach if data were reported for other age bands (eg, 0–11 months; appendix p 28).¹⁵

We estimated the number of hPIV-associated in-hospital ALRI deaths by combining the estimates of hospital admissions and hCFRs of hPIV-associated ALRI.²¹ The adjusted hospital admissions and hCFRs (accounting for missing hPIV-4) were used in the analysis. Similar to morbidity estimation, the global estimates of mortality were calculated as the sum of the estimates by the three age groups and by child mortality settings.

We estimated the number of overall hPIV-associated ALRI deaths by combining the estimates of hPIV-associated in-hospital deaths and the ratio of overall deaths to in-hospital deaths (labelled as an inflation factor). Details of data sources and analyses of the inflation factor have been described previously (appendix pp 19, 20).¹⁵ Briefly, the median ratio of overall ALRI deaths to in-hospital ALRI deaths at eight sites in six countries with high child mortality was extrapolated to other countries with high child mortality. For settings with low child mortality, the reciprocal of the proportion

Department of Medical Microbiology, Vestre Viken Hospital Trust, Drammen, Norway (M Mathisen PhD); Área de Investigación en Vacunas, Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Salud Pública, Valencia, Spain (A Mira-Iglesias MSc); Barcelona Global Health Institute, Hospital Clínic-University of Barcelona, Barcelona, Spain (C Moraleda PhD); Infectious Pediatric Diseases Section, Hospital Universitario de Octubre, Universidad Complutense, Research Institute Hospital de Octubre, Madrid, Spain (C Moraleda); Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan (M Okamoto PhD, Prof H Oshitani MD); KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya (B E Owor PhD); Fogarty International Center, National Institutes of Health, Bethesda, MD, USA (Z A Rasmussen MD); Vienna Vaccine Safety Initiative, Berlin, Germany (Prof B A Rath MD); Université Bourgogne-Franche Comté, Besançon, France (Prof B A Rath); Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran (V Salimi PhD); Division of Global Health Protection, Thailand Ministry of Public Health and US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand (P Sawatwong PhD); KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research, Kilifi, Kenya (Prof J A G Scott FRCP); Nuffield Department of Tropical Medicine, Oxford University, Oxford, UK (Prof J A G Scott); Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK (Prof J A G Scott); Department of Pediatrics, Section of Infectious Diseases, University of Colorado, School of Medicine, Aurora, CO, USA (Prof E A F Simões MD); Department of Epidemiology and Center for Global Health, Colorado School of Public Health, Aurora, CO, USA (Prof E A F Simões);

Epidemiology Department, Ministry of Health, Santiago, Chile (V Sotomayor MPH); Department of Global Health and Development, Boston University School of Public Health, Boston, MA, USA (Prof D M Thea MD); Department of Medical Virology, National Health Laboratory Service and School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa (F K Treurnicht PhD); Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan (Prof L-M Yoshida PhD);

of children with pneumonia symptoms who received care, measured in Multiple Indicator Cluster Surveys, Demographic and Health Surveys, and other national surveys, was used as a proxy for inflation factor.²² The median value was extrapolated to other countries with low child mortality without data.

On the basis of hPIV-associated ALRI burden estimates, we estimated the ALRI burden attributable to hPIV by accounting for the attributable fraction of hPIV in hPIV-associated ALRI cases and deaths. Two pooled analyses of multi-country data showed that the attributable fraction of hPIV-associated ALRI cases varied by type;^{6,7} we estimated the average attributable fraction of hPIV cases and hospital admissions using type-specific attributable fraction estimates and the pooled proportion of four hPIV-type cases (appendix p 22). The attributable fraction of hPIV-associated ALRI

deaths was calculated using the attributable fraction of hPIV-associated ALRI cases and the ratio between the hCFRs of hPIV-positive ALRI and hPIV-negative ALRI. We assumed that the hCFR of hPIV-negative ALRI was equal to the hCFR of hPIV-positive ALRI that were not deemed attributable to hPIV (appendix pp 23, 24).

Sensitivity analyses

For hPIV-associated ALRI morbidity and in-hospital deaths, we reported estimates by country development regions according to UNICEF definitions and by World Bank income levels (low-income and lower-middle-income, upper-middle-income, and high-income) in sensitivity analyses.^{23,24} Additionally, we estimated the range of hPIV-associated ALRI hospital admissions by applying the proportion of those positive for hPIV in ALRI hospital admissions and the estimates of all-cause ALRI hospital admissions among children younger than 5 years for 2015–16 (appendix p 13).^{25,26} We estimated the overall hPIV-associated ALRI mortality for settings with high child mortality in a sensitivity analysis by applying the proportion of ALRI deaths positive for hPIV to the number of ALRI deaths among children younger than 5 years for 2017.¹ The proportion of ALRI deaths positive for hPIV was estimated using data from 12 hospital-based studies retrieved with our systematic review (including five PERCH sites) from high mortality burden settings in which at least 90% of ALRI cases were tested and at least five ALRI deaths were identified during the study period (appendix p 21). In the sensitivity analysis, the hPIV-attributable ALRI mortality for settings with high child mortality was estimated using another approach by applying the proportion of hPIV-attributable ALRI deaths to the number of ALRI deaths among children younger than 5 years. The proportion of hPIV-attributable ALRI deaths was estimated using data in the period from December, 2016, to October, 2019, from the Child Health and Mortality Prevention Surveillance (also known as CHAMPS; appendix p 25).²⁷

We report the estimates from the main analysis. Sensitivity results are in the appendix (pp 10–16, 18, 21, 25), as are details of the included studies (pp 39–58). All analyses were done in R (version 3.6.1).^{28,29} This study was done and reported in accordance with the Guidelines for Accurate and Transparent Health Estimates Reporting recommendations (appendix p 72).³⁰ The systematic review protocol was registered on PROSPERO (CRD42019148570).

Role of the funding source

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Results

We identified 203 studies with data on hPIV-associated ALRI community incidence rates (13 studies), hospital




Figure: Flow diagram for study selection for hPIV-associated ALRI burden

A study was defined as a dataset from one site in one published paper or from one research group in the network. Some studies provided more than one type of data, so the sum of studies across types was larger than the total number of included studies. ALRI=acute lower respiratory infection. hCFR=in-hospital case-fatality ratio. hPIV=human parainfluenza virus.

| | Low-income and lower-middle-income countries | Upper-middle-income countries | High-income countries | Low child mortality settings | High child mortality settings | Global estimates (low and high child mortality settings) |
|----------------------------|--|-------------------------------|-----------------------|------------------------------|-------------------------------|--|
| 0–5 months | | | | | | |
| Number of studies | 5 | 1 | 0 | 0 | 6 | .. |
| Incidence (95% CI)* | 43.2 (11.7–146.4) | .. | .. | .. | 51.1 (18.1–136.0) | .. |
| ALRI cases (thousands; UR) | 1913 (545–6723) | .. | .. | .. | 2352 (863–6415) | .. |
| 6–11 months | | | | | | |
| Number of studies | 5 | 1 | 0 | 0 | 6 | .. |
| Incidence (95% CI)* | 89.3 (65.7–120.2) | .. | .. | .. | 85.7 (66.0–110.6) | .. |
| ALRI cases (thousands; UR) | 3920 (2903–5294) | .. | .. | .. | 3911 (3025–5056) | .. |
| 12–59 months | | | | | | |
| Number of studies | 4 | 1 | 0 | 0 | 5 | .. |
| Incidence (95% CI)* | 28.5 (15.9–50.6) | .. | .. | .. | 28.5 (17.9–45.2) | .. |
| ALRI cases (thousands; UR) | 9774 (5497–17386) | .. | .. | .. | 10164 (6413–16115) | .. |
| 0–59 months | | | | | | |
| Number of studies† | 7 (3) | 1 | 4 (3) | 4 (3) | 8 (3) | .. |
| Incidence (95% CI)* | 37.7 (27.8–51.0) | .. | 37.8 (18.5–77.3) | 37.8 (18.5–77.3) | 38.8 (30.1–50.2) | .. |
| ALRI cases (thousands; UR) | 16 247 (12 013–21 978) | .. | 2395 (1176–4880) | 8670 (4258–17 664) | 17 417 (13 504–22 467) | 26 087 (17 762–40 131) |

The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for high child mortality and low child mortality settings. The incidence rate was adjusted to account for the missing hPIV-4 (ten studies). In one study, only the hPIV-3 rate was available; the rate was adjusted to account for the missing hPIV-1, hPIV-2, and hPIV-4. For the remaining one study, four types were detected and the rate was not adjusted. ALRI=acute lower respiratory infections. hPIV=human parainfluenza virus. UR=uncertainty range. *Incidence (per 1000 children per year) from meta-analyses. †The number in the parentheses shows the number of imputed studies.

Table 1: Estimates of the incidence (per 1000 children per year), and number of hPIV-associated ALRI cases in age groups of children younger than 5 years in 2018, by World Bank income level and child mortality setting

admission rates (38 studies), proportion of those positive for hPIV in ALRI hospital admissions (168 studies), and hCFRs (58 studies; figure). There were 41 unpublished studies from the collaborative network and 162 studies from published literature. By World Bank income levels, eight studies were from low-income countries, 37 from lower-middle-income countries, 109 from upper-middle-income countries, and 49 from high-income countries. The number of studies is summarised in the appendix (pp 7–8).

We identified 13 studies with incidence rates of hPIV-associated ALRI. There were 12 studies with data for 0–59 months (including imputed data). Seven studies reported the rates for before 2010. One study detected all four hPIV types, one study only detected hPIV-3, and other studies detected hPIV-1 to hPIV-3. The adjusted hPIV-associated ALRI incidence rate meta-estimate was 38.8 (95% CI 30.1–50.2) per 1000 children per year for ages 0–59 months for settings with high child mortality, and 37.8 (18.5–77.3) per 1000 children per year for settings with low child mortality. The high incidence in low child mortality settings was mainly driven by two Australian studies (one for 1996–99, and the other for 2010–14). We estimated 26.1 million (UR 17.8–40.1) hPIV-associated ALRI cases globally in children younger than 5 years (table 1).

There were 38 studies with hPIV-associated ALRI hospital admission rates, including 26 studies reporting data by three narrow age bands: 0–5 months,

6–11 months, or 12–59 months. Only nine studies reported data for all four hPIV types. The adjusted hospital admission rate was higher in infants (0–11 months) than children aged 12–59 months across World Bank income levels and child mortality settings. Particularly in settings with high child mortality, the rate was 5.8 (95% CI 3.7–9.2) per 1000 children per year for ages 0–5 months, 4.7 (3.2–6.7) for 6–11 months, and 0.7 (0.5–1.2) for children aged 12–59 months (table 2). In the main analysis (by child mortality settings), we estimated 1007000 (UR 601000–1750000) hPIV-associated ALRI hospital admissions globally in children younger than 5 years. Of these hospital admissions, 35% were in children aged 0–5 months, 26% were in children aged 6–11 months, and 39% were in children aged 12–59 months.

There were 13 studies reporting hospital admission rates for hPIV-associated ALRI with hypoxaemia by age band, including nine studies reporting data for all four hPIV types. In the analysis stratified by child mortality settings, we estimated 162000 (UR 88000–779000) hospital admissions for hPIV-associated ALRI with hypoxaemia (adjusted for missing hPIV-4) in children aged 0–59 months globally, accounting for 16% of the hPIV-associated ALRI hospital admissions.

We identified 58 studies reporting the hCFRs of hPIV-associated ALRI in children younger than 5 years, including 27 studies with data stratified by three narrow age bands. Eight studies did not report data for hPIV-4.

Department of Paediatrics & Child Health, Medical Research Council Unit on Child & Adolescent Health, University of Cape Town, Cape Town, South Africa (Prof H J Zar PhD)

Correspondence to: Prof Harish Nair, Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh EH8 9AG, UK harish.nair@ed.ac.uk

See Online for appendix
For more on CHAMPS see <https://champshealth.org/>

| | Low-income and lower-middle-income countries | Upper-middle-income countries | High-income countries | Low child mortality settings | High child mortality settings | Global estimates (low and high child mortality settings) |
|--|--|-------------------------------|-----------------------|------------------------------|-------------------------------|--|
| hPIV-associated ALRI 0–5 months | | | | | | |
| Number of studies | 7 | 6 | 4 | 7 | 10 | .. |
| Hospital admission rate (95% CI) | 3·8 (1·8–7·8) | 5·7 (3·0–10·5) | 5·5 (3·1–9·9) | 3·6 (1·8–7·0) | 5·8 (3·7–9·2) | .. |
| Hospital admissions (thousands; UR) | 168 (81–349) | 105 (56–196) | 35 (20–62) | 83 (42–163) | 267 (170–420) | 350 (212–583) |
| hPIV-associated ALRI 6–11 months | | | | | | |
| Number of studies | 7 | 5 | 3 | 5 | 10 | .. |
| Hospital admission rate (95% CI) | 3·5 (1·7–7·0) | 3·8 (1·9–7·6) | 3·5 (1·9–6·5) | 2·0 (0·9–4·6) | 4·7 (3·2–6·7) | .. |
| Hospital admissions (thousands; UR) | 154 (76–311) | 70 (35–139) | 22 (12–41) | 46 (20–104) | 214 (149–310) | 260 (169–413) |
| hPIV-associated ALRI 12–59 months | | | | | | |
| Number of studies | 8 | 8 | 4 | 8 | 12 | .. |
| Hospital admission rate (95% CI) | 0·8 (0·4–1·4) | 0·8 (0·4–1·6) | 0·8 (0·2–2·9) | 0·8 (0·3–1·9) | 0·7 (0·5–1·2) | .. |
| Hospital admissions (thousands; UR) | 274 (147–512) | 117 (59–233) | 41 (11–153) | 147 (59–368) | 250 (162–386) | 396 (220–753) |
| hPIV-associated ALRI 0–59 months | | | | | | |
| Hospital admissions (thousands; UR) | 596 (304–1171) | 292 (150–569) | 98 (42–257) | 276 (121–634) | 731 (480–1116) | 1007 (601–1750) |
| hPIV-associated ALRI with hypoxaemia 0–5 months | | | | | | |
| Number of studies | 6 | 3 | 1 | 2 | 7 | .. |
| Hospital admission rate (95% CI) | 0·6 (0·3–1·6) | 1·8 (1·1–3·0) | .. | 0·2 (0·1–0·3) | 1·4 (0·8–2·4) | .. |
| Hospital admissions (thousands; UR) | 27 (12–61) | 33 (20–55) | .. | 5 (3–8) | 64 (37–111) | 69 (40–119) |
| hPIV-associated ALRI with hypoxaemia 6–11 months | | | | | | |
| Number of studies | 6 | 3 | 1 | 2 | 7 | .. |
| Hospital admission rate (95% CI) | 0·3 (0·1–0·9) | 1·0 (0·5–1·8) | .. | 0·1 (0·0–0·2) | 0·8 (0·5–1·4) | .. |
| Hospital admissions (thousands; UR) | 13 (4–39) | 18 (10–35) | .. | 2 (0–14) | 36 (22–61) | 39 (22–75) |
| hPIV-associated ALRI with hypoxaemia 12–59 months | | | | | | |
| Number of studies | 6 | 6 | 1 | 4 | 8 | .. |
| Hospital admission rate (95% CI) | 0·1 (0·1–0·2) | 0·1 (0·0–1·2) | .. | 0·1 (0·0–4·4) | 0·1 (0·1–0·2) | .. |
| Hospital admissions (thousands; UR) | 34 (24–48) | 15 (1–223) | .. | 18 (1–534) | 36 (25–50) | 54 (26–584) |
| hPIV-associated ALRI with hypoxaemia 0–59 months | | | | | | |
| Hospital admissions (thousands; UR) | 74 (40–149) | 66 (31–313) | .. | 25 (4–556) | 137 (84–223) | 162 (88–779) |

The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for settings with high child mortality and low child mortality. The hospital admission rate was adjusted to account for the missing hPIV-4. Hospital admission rates from meta-analyses. ALRI=acute lower respiratory infections. hPIV=human parainfluenza virus. UR=uncertainty range.

Table 2: Hospital admission rates (per 1000 children per year), and hospital admissions of hPIV-associated ALRI in age groups of children younger than 5 years in 2018, by World Bank income level and child mortality setting

The hCFR meta-estimates did not vary much by age band; however, we observed a 1–2-times difference across settings. Children in countries with high child mortality and in lower-middle-income countries generally had the highest hCFRs (2·3–3·6% for high child mortality settings; 2·0–3·9% for lower-middle-income countries; table 3). We estimated 25700 (UR 12000–56500) hPIV-associated in-hospital ALRI deaths in children younger than 5 years. Of these deaths, approximately 42% were in children aged 0–5 months, 24% were in children aged 6–11 months, and 34% were in children aged 12–59 months (table 3).

We estimated a median inflation factor of 2·2 for settings with high child mortality and 1·3 for those with low child mortality (appendix p 20). Combining the estimates of inflation factors and hPIV-associated in-hospital ALRI mortality, we estimated 47600 (UR 23400–97100) overall

hPIV-associated ALRI deaths in high child mortality settings, and 53000 (25300–113500) deaths globally.

We estimated an average attributable fraction of 72% for hPIV-associated ALRI cases, and 65% for hPIV-associated ALRI deaths among children younger than 5 years (table 4; appendix pp 20–22). Thus, we estimated that 18·8 million (UR 12·8–28·9) ALRI cases, 725000 (433000–1260000) ALRI hospital admissions, and 34400 (16400–73800) ALRI deaths could be attributed to hPIV in children younger than 5 years globally. There were 30900 (UR 15200–63100) hPIV-attributable ALRI deaths in settings with high child mortality.

We did several sensitivity analyses to estimate hospital admissions, in-hospital deaths, and overall deaths of hPIV-associated ALRI, as well as hPIV-attributable ALRI deaths. For global hPIV-associated ALRI hospital admissions, the estimates in children younger than 5 years

| | Low-income and lower-middle-income countries | Upper-middle-income countries | High-income countries | Low child mortality settings | High child mortality settings | Global estimates (low and high child mortality settings) |
|-------------------|--|-------------------------------|-----------------------|------------------------------|-------------------------------|--|
| Number of studies | 15 | 8 | 4 | 7 | 20 | .. |
| 0–5 months | | | | | | |
| hCFR, % (95% CI) | 3.9 (2.1–7.3) | 2.4 (1.3–4.6) | 0.9 (0.2–3.6) | 1.3 (0.6–3.1) | 3.6 (2.2–5.8) | .. |
| Deaths (UR) | 6600 (2600–17 000) | 2500 (1100–6100) | 300 (100–1500) | 1100 (400–3100) | 9600 (5000–18 600) | 10 700 (5400–21 700) |
| 6–11 months | | | | | | |
| hCFR, % (95% CI) | 2.0 (0.5–7.4) | 3.8 (2.2–6.6) | 1.2 (0.3–4.7) | 2.6 (1.0–6.9) | 2.3 (0.9–5.8) | .. |
| Deaths (UR) | 3100 (700–13 800) | 2700 (1100–6400) | 300 (100–1200) | 1200 (300–4200) | 4900 (1800–13 300) | 6100 (2200–17 300) |
| 12–59 months | | | | | | |
| hCFR, % (95% CI) | 3.5 (2.2–5.6) | 1.9 (0.8–4.1) | 0.9 (0.4–1.9) | 1.2 (0.7–2.3) | 2.8 (1.8–4.4) | .. |
| Deaths (UR) | 9600 (4500–20 900) | 2200 (800–6400) | 400 (100–1700) | 1800 (600–5200) | 7000 (3800–13 000) | 8800 (4400–18 100) |
| 0–59 months | | | | | | |
| Deaths (UR) | 19 400 (7800–50 800) | 7400 (3000–18 900) | 1000 (200–4100) | 4100 (1400–12 400) | 21 600 (10 600–44 100) | 25 700 (12 000–56 500) |

The median value of the 2018 younger than 5 years mortality rate was used as the cutoff point for settings with high child mortality and low child mortality. The in-hospital deaths were estimated using adjusted hospital admissions and adjusted hCFRs to account for the missing hPIV-4. hCFR estimates were from meta-analyses. ALRI=acute lower respiratory infections. hCFR=in-hospital case-fatality ratio. hPIV=human parainfluenza virus. UR=uncertainty range.

Table 3: hCFR meta-estimates of hPIV-associated ALRI and in-hospital deaths in age groups of children younger than 5 years in 2018, by World Bank income level and child mortality setting

ranged from 986 000 to 1 007 000 in analyses by different stratification groups (appendix pp 11, 12); the proportion-based approach yielded a broader range (ie, from 452 000 to 1 443 000 admissions; appendix p 13). The point estimate of global in-hospital deaths ranged from 25 700 to 27 800 in children younger than 5 years, and an estimated 70% of the global in-hospital deaths occurred in lower-middle-income countries (19 400 of 27 800) based on the results by World Bank income level (appendix pp 14, 15). We estimated 56 100 (UR 36 500–87 400) hPIV-associated ALRI deaths and 45 500 (24 900–91 700) hPIV-attributable ALRI deaths in children younger than 5 years in settings with high child mortality in sensitivity analyses (appendix pp 21, 25).

Between 73% and 100% (varying by outcome) of the studies had a low risk in study design, 46–65% of the studies had a low risk in adjustment for health-care use, 59–77% of studies had a low risk in patient groups excluded, 54–93% of studies had a low risk in case definition, 42–93% of studies had a low risk in sampling strategy, and 67–77% of studies had a low risk in test methods (appendix p 8). Differences in estimates were found for all outcomes (appendix pp 43–44). For example, the unadjusted incidence rate of hPIV-associated ALRI ranged from 17.3 (95% CI 9.3–31.8) to 56.5 (38.1–82.9) per 1000 children per year for ages 0–59 months between studies. Hospital admission rates of hPIV-associated ALRI ranged from 0.8 (0.1–5.4) to 30.1 (18.2–49.3) per 1000 children per year for 0–5 months, 0.6 (0.4–0.8) to 18.1 (9.8–33.4) for 6–11 months, and 0.0 (0.0–1000.0) to 6.8 (5.3–8.7) for 12–59 months between studies.

| | Attributable fraction (%)* | Global hPIV-associated burden estimates (UR) | Global hPIV-attributable burden estimates† (UR) |
|--------------------------------------|----------------------------|--|---|
| ALRI cases (millions) | 72%‡ | 26.1 (17.8–40.1) | 18.8 (12.8–28.9) |
| ALRI hospital admissions (thousands) | 72% | 1007 (601–1750) | 725 (433–1260) |
| ALRI deaths | 65%§ | 53 000 (25 300–113 500) | 34 400 (16 400–73 800) |

ALRI=acute lower respiratory infections. hPIV=human parainfluenza virus. UR=uncertainty range. *The fraction of ALRI cases and deaths with laboratory-confirmed hPIV that are attributable to hPIV. †Applying the corresponding attributable fraction to the estimates of hPIV-associated burden. ‡The attributable fraction for hPIV-associated ALRI cases was calculated using type-specific attributable fraction and prevalence. Details and the references are in the appendix (p 19). §The attributable fraction for hPIV-associated ALRI deaths was modelled using the attributable fraction for hPIV cases and the ratio of case-fatality between hPIV-attributable cases and hPIV-associated cases. Details are in the appendix (pp 20, 21).

Table 4: Estimates of global number of hPIV-attributable ALRI cases, hospital admissions, and deaths among children younger than 5 years in 2018 using attributable fraction of hPIV-associated ALRI

Discussion

We report the first global hPIV-associated and hPIV-attributable ALRI burden estimates among children younger than 5 years. A comparison between available all-cause ALRI burden estimates and our hPIV-specific estimates suggests that hPIV could be detected in 19% of ALRI cases (26 of 138 million), 6–20% of ALRI hospital admissions (1 of 5–16 million), and 7% of ALRI mortality (53 000 of 809 000) among children younger than 5 years globally.^{1,25,26} Of note, the number of hPIV-associated ALRI cases was developed on the basis of few data, and therefore needs to be verified with additional data. hPIV can be detected in the upper respiratory tract in healthy children and mere isolation does not indicate a causal association for ALRI; the use of attributable fraction therefore allowed

us to estimate the proportion of ALRI cases in which hPIV is isolated and is the probable cause. Estimates from this analysis suggested that 13% of ALRI cases (18·8 of 138·0 million), 4–14% ALRI hospital admissions (0·7 of 5·0–16·0 million), and 4% of ALRI mortality (34400 of 809000) could be attributed to hPIV. When considered in the context of our other virus-specific ALRI burden estimates, hPIV-attributable ALRI hospital admissions and mortality in children younger than 5 years seem higher than for human metapneumovirus (approximately 500000 human metapneumovirus-attributable ALRI hospital admissions and 11000 deaths), but similar to that for seasonal influenza virus (approximately 700000 influenza virus-attributable ALRI hospital admissions), and lower than the burden for respiratory syncytial virus.^{15,21,31} These estimates indicate that hPIV is an important virus, in that it is a substantial burden, related to ALRI in young children.

Similar to other viruses, a large proportion of the hPIV-associated ALRI burden occurred in infants younger than 1 year (61% of hPIV hospital admissions and 66% of hPIV in-hospital deaths), and children in low-income and lower-middle-income countries had the highest hCFRs.^{15,21,26} The high burden in infants might reflect their immature immune systems and decay of maternal antibodies.^{32,33} Children aged 12–59 months still had high hCFRs compared with infants, which might reflect the virulence of hPIV and have implications for development of prevention strategies. Differences in data availability exist for different viruses, and the current hPIV burden estimates are based on fewer datapoints than those for seasonal influenza virus and respiratory syncytial virus, and will probably be refined when more data are available in future.

Our global burden estimates were generally robust in sensitivity analyses. The estimates for global hPIV-associated ALRI hospital admissions and in-hospital mortality, and overall hPIV-associated ALRI mortality, were all similar in different stratification groups and other sensitivity analyses (appendix pp 11–15, 21, 25). We reported a more conservative estimate of hPIV-attributable mortality in our main analysis (using the attributable fraction approach), and the point estimate increased by 47% (30900/45500) in settings with high child mortality in a sensitivity analysis (appendix p 25). We calculated the attributable fraction of hPIV in hPIV-confirmed cases and deaths using data from two pooled analyses, which were mainly from settings with high child mortality.^{6,7} The estimates might have limited the representativeness of these data for low child mortality settings. The attributable fraction approach, estimated using data from case-control studies, indicates the probable true burden of hPIV in ALRI. However, making a causal inference is a challenge when using data from observational studies.

In general, we used the same analytical strategy as used previously,^{15,21} with one adaptation in the current

analysis to enable us to report burden estimates for the four hPIV types based on studies that reported data either for three types (hPIV-1 to hPIV-3) or four types. Our four hPIV-type ALRI burden estimates were adjusted on the basis of two key variables. One variable was the proportion of hPIV-4 in all hPIVs (12%), which was estimated in a pooled analysis of 24 hospital-based studies. We extrapolated this prevalence to community settings. There was only one community-based study detecting all four types and reporting hPIV-4 in 20% of hPIV cases. We consider the extrapolation to improve the generalisation of this adjustment, although it might have led to a conservative estimate of hPIV-4 associated ALRI cases. The second set of variables, hCFRs for four hPIV types, was estimated using data from five studies from countries with high child mortality. The type-specific hCFRs had wide and overlapping confidence intervals, especially for hPIV-2 and hPIV-4, reflecting the substantial variation across studies and limited precision because of the small case numbers for the two types. Additional data on hPIV type-specific hCFRs might help to refine the analyses and estimates.

The wide URs of the burden estimates reflected the differences in hPIV epidemiology between populations, methodological differences, and paucity of data. As shown in the described risk of bias of studies, methodological heterogeneity between studies could have probably biased our estimates (appendix p 8). hPIV-associated ALRI hospital admissions could have been overestimated in 27% (seven of 26 studies; appendix p 8) of hospital admission studies, which adopted broader case definitions (eg, patients with ALRI admitted to hospital; patients with ALRI or croup admitted to hospital). Underdetection (a detection rate of less than 90%) was observed in 23% of studies in the analysis of hPIV-associated ALRI hospital admissions. We adjusted for underdetection as previously described by assuming the percent positivity for hPIV was the same in those tested and untested, and incorporated differences in rates of underdetection between studies in the meta-analyses of incidence and hospital admission rates.¹⁵ We did not adjust for underdetection when estimating hCFRs; the underdetection could cause an underestimation of hCFR estimates, because severe cases and deaths are usually less likely to be sampled compared with non-severe cases.³⁴ We found a consistent result in our data showing that the hCFR in those tested was lower than in those untested (appendix p 29). Approximately 32% (12/38; appendix p 8) of studies with data on incidence and hospital admission rates used traditional test methods (eg, indirect immunofluorescence assay, culture, and mixed test methods). These traditional test methods have a similar specificity but lower sensitivity than molecular tests, and thus could result in an underestimation of the true burden.^{35,36} Most hospital-based studies used nasopharyngeal specimens solely or in combination with other respiratory tract specimens

(appendix pp 49–51), and it has been reported that nasopharyngeal specimens have similar or higher sensitivity in detecting hPIV than do other upper respiratory tract specimens.^{37–40} Additionally, the inclusion of old data (34% [17 of 50 studies] of the data in the main analysis were from the pre-2010 period) could have biased our estimates. We chose 2010 as the cutoff because more studies have started to use molecular tests since the 2009 influenza pandemic. The included data suggest that approximately 81% (13/16) of hospital-based studies used molecular tests since 2010 compared with 50% (five of ten studies) before 2010. Estimation of inflation factors (and overall hPIV-associated ALRI mortality) in this study was based on the same data as we used previously (data on care-seeking for non-specific pneumonia symptoms and deaths) and so was susceptible to similar potential limitations and assumptions (appendix p 19).¹⁵

In general, our hPIV ALRI burden estimates, derived from laboratory-confirmed data, probably show the lower limit of the true burden of hPIV because of the challenge in systematically diagnosing and detecting hPIV infections, and many factors that can affect test results and lead to a false negative diagnosis. Additionally, the estimates of hospital admissions have probably underestimated the potential burden of hPIV-associated ALRI on health-care services, especially in regions with a low health-care capacity and poor access to care. Nevertheless, our hPIV-associated and hPIV-attributable ALRI burden estimates suggest that hPIV is a notable virus in childhood ALRI. These estimates should help to guide health investment priorities and resource allocation. By raising awareness of the disease and health-care burden these estimates might also encourage and inform investment to accelerate the development of targeted prevention and treatment interventions.

Contributors

HN and HC conceptualised the study. XW led the literature review. KAM and YL independently screened the literature and extracted data. XW led the data analysis with contributions from YL, XW, HN, HC, MD-K, SAM, and CC led the data interpretation. XW wrote the first draft of the manuscript with input from HN, HC, MD-K, SAM, and CC. XW and HN had full access to all the data in the study and HN had final responsibility for the decision to submit for publication. All named authors of the Respiratory Virus Global Epidemiology Network contributed to development of the analysis plan, collection, and analysis of primary data, data interpretation, and critically reviewed the revised initial draft of the manuscript. All members of the Respiratory Virus Global Epidemiology Network contributed to data collection, data analysis, and critically reviewed the manuscript. All authors read and approved the draft for finalisation.

Respiratory Virus Global Epidemiology Network

Harish Nair, Harry Campbell, Xin Wang, You Li, Kenneth A McLean, Ting Shi (Centre for Global Health, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK); Marcela Echavarría, Noelia Reyes (Clinical Virology Unit, Centro de Educación Médica e Investigaciones Clínicas “CEMIC”, Argentina); Angela Gentile (Epidemiology Department, Austral University; Ricardo Gutiérrez Children Hospital, Argentina); Florencia Lucion, María Del Valle Juarez (Ricardo Gutiérrez Children Hospital in Buenos Aires, Argentina); W Abdullah Brooks (Department of International Health, Johns Hopkins

Bloomberg School of Public Health, Baltimore, MD, USA); Nusrat Homaira (International Centre for Diarrhoeal Disease Research, Bangladesh, Dhaka, Bangladesh; Discipline of Paediatrics, School of Women’s and Children’s Health, The University of New South Wales, Sydney, Australia); Rodrigo A Fasce (Public Health Institute of Chile, Chile); Viviana Sotomayor (Epidemiology Department, Ministry of Health, Chile); Olga Lopez, David Ortiz (Hospital Dr Ernesto Torres Galdames, Iquique, Chile); Martha Werner, Ivan Rodriguez (Hospital Dr Guillermo Grant Benavente, Chile); Andrea Gutierrez (Seremi de Salud Región del Bio Bio, Chile); Barbara A Rath, Patrick Obermeier, Brunhilde Schweiger, Maren Alchikh (Vienna Vaccine Safety Initiative, Berlin, Germany; Université Bourgogne-Franche Comté, France); Anand Krishnan, Avinash Choudekar, Rakesh Kumar (All India Institute of Medical Sciences, New Delhi, India); Shobha Broor (Shree Guru Gobind Singh Tercentenary University Gurgaon, Haryana, India); Vahid Salimi (Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran); Najwa Khuri-Bulos, Natasha Halasa (University of Jordan school of medicine, Jordan); Betty E Owor, D James Nokes, Nickson Murunga (KEMRI-Wellcome Trust Research Programme, Coast, Kilifi, Kenya); Quique Bassat (ISGlobal, Hospital Clínic–University of Barcelona, Barcelona, Spain; Centro de Investigación em Saúde de Manhíça, Maputo, Mozambique; Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain; Pediatric Infectious Diseases Unit, Pediatrics Department, Hospital Sant Joan de Déu, University of Barcelona, Barcelona, Spain; Consorcio de Investigación Biomédica en Red de Epidemiología y Salud Pública, Madrid, Spain); Cinta Moraleda (ISGlobal, Hospital Clínic–University of Barcelona, Barcelona, Spain; Infectious Pediatric Diseases Section, Hospital Universitario de Octubre, Universidad Complutense, Research Institute Hospital de Octubre, Madrid, Spain); Miguel Lanasa, Lola Madrid, Rachid Benmessaoud (ISGlobal, Hospital Clínic–Universitat de Barcelona, Barcelona, Spain); Imane Jroundi (Unit of training and research in public health and social accountability, School of medicine and pharmacy, University Mohammed V in Rabat, Morocco); Sozinho Acácio (Centro de Investigação em Saúde de Manhíça, Maputo, Mozambique); Tor A Strand (Innland Hospital Trust, Lillehammer, Norway; the Centre for International Health, University of Bergen, Norway); Sudha Basnet (Department of Child Health, Tribhuvan University, Kathmandu, Nepal; the Centre for International Health, University of Bergen, Norway); Maria Mathisen (Department of Medical Microbiology, Vestre Viken Hospital Trust, Drammen, Norway); Arun Sharma (Child Health Department, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal); Zeba A Rasmussen, Julia M Baker, Elizabeth D Thomas, Alexandra F Jamison (Fogarty International Center, National Institutes of Health, USA); Maria Deloria-Knoll, Katherine L O’Brien, Melissa M Higdon, Meredith Haddix (Department of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA); Pongpun Sawatwong (Division of Global Health Protection, Thailand Ministry of Public Health - US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand); Malinee Chittaganpitch (Medical Sciences Technical Office, Department of Medical Sciences, Ministry of Public Health, Thailand); Henry C Baggett (Global Disease Detection Center, Thailand Ministry of Public Health - US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand; Division of Global Health Protection, US Centers for Disease Control and Prevention, Atlanta, GA, USA); Donald M Thea (Department of Global Health and Development, Boston University School of Public Health, Boston, MA, USA); Phil Seidenberg (Department of Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Department of Emergency Medicine, University of New Mexico, Albuquerque, NM, USA); Lawrence Mwanayanda (Department of Global Health and Development, Boston University School of Public Health, Boston, MA, USA; Right To Care-Zambia, Lusaka, Zambia); Stephen RC Howie (Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, London, UK; Department of Paediatrics, University of Auckland, New Zealand); Syed MA Zaman (Medical Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine; London School of Hygiene & Tropical Medicine, London, UK); Jessica L McLellan (Medical

Research Council Unit The Gambia at London School of Hygiene & Tropical Medicine, London, UK; The University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada); Shabir A Madhi, Vicky L Baillie, Marta Nunes (Medical Research Council: Respiratory and Meningeal Pathogens Research Unit University of the Witwatersrand, Johannesburg, South Africa); David P Moore (Medical Research Council: Respiratory and Meningeal Pathogens Research Unit University of the Witwatersrand, Johannesburg, South Africa); Department of Paediatrics & Child Health, Chris Hani Baragwanath Academic Hospital and University of the Witwatersrand, South Africa); Doli Goswami, Mustafizur Rahman, Mohammed Ziaur Rahman (International Centre for Diarrhoeal Disease Research, Bangladesh); J Anthony G Scott (KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya; Nuffield Department of Tropical Medicine, Oxford University, Oxford, UK); Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK); Juliet O Awori, Susan Morpeth (KEMRI-Wellcome Trust Research Programme, Centre for Geographic Medicine Research, Coast, Kilifi, Kenya; Nuffield Department of Tropical Medicine, Oxford University, Oxford, UK); Karen L Kotloff (Department of Pediatrics and Department of Medicine, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA); Milagritos D Tapia (Department of Pediatrics, Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, USA); Samba O Sow (Centre pour le Développement des Vaccins – Mali, Bamako, Mali); Marilla G Lucero, Leilani T Nillos, Socorro Lupisan, Vina Lea Arguelles (Research Institute for Tropical Medicine, Philippines); Hatoshi Oshitani, Michiko Okamoto (Department of Virology, Tohoku University Graduate School of Medicine, Sendai, Japan); Cheryl Cohen, Orianka Hellferscee, Sibongile Walaza, Anne von Gottberg (Centre for Respiratory Disease and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa and University of the Witwatersrand, Johannesburg, South Africa); Omphile Mekgoe (Department of paediatrics, Klerksdorp-Tshepong Hospital Complex, Klerksdorp, South Africa); Florette K Treurnicht (Department of Medical Virology, National Health Laboratory Service, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa); Halima Dawood (Infectious Diseases Unit, Greys hospital, Pietermaritzburg, South Africa and Caprisa, University of Kwazulu Natal, South Africa); Fathima Naby (Pietermaritzburg Metropolitan Hospitals, University of KwaZulu-Natal, South Africa); Heather J Zar (Department of Paediatrics & Child Health and MRC unit on Child & Adolescent Health, University of Cape Town, South Africa); Mark P Nicol (University of Cape Town; National Health Laboratory Services, South Africa); Eric A F Simoes (Department of Pediatrics, Section of Infectious Diseases, School of Medicine, University of Colorado; Department of Epidemiology and Center for Global Health, Colorado School of Public Health, Aurora, CO, USA); Lay-Myint Yoshida, Michiko Toizumi (Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan); Dang Duc Anh, Hien-Anh Thi Nguyen (National Institute of Hygiene and Epidemiology, Hanoi, Vietnam); Ainara Mira-Iglesias, Javier Díez-Domingo, Joan Puig-Barberà (Àrea de Investigació en Vacunes, Fundació para el Foment de la Investigació Sanitària y Biomèdica de la Comunitat Valenciana, Valencia, Spain); F Xavier López-Labrador (Àrea de Genòmica y Salud, Fundació para el Foment de la Investigació Sanitària y Biomèdica de la Comunitat Valenciana, Valencia, Spain; Consorcio de Investigación Biomédica de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Madrid, Spain).

Declaration of interests

YL reports grants from WHO outside the submitted work. MD-K reports grants from Merck and Pfizer, and personal fees from Merck outside the submitted work. SAM reports grants from the Bill & Melinda Gates Foundation, GlaxoSmithKline, Minervax, and Pfizer; and personal fees from the Bill & Melinda Gates Foundation outside the submitted work. CC reports grants from PATH, Sanofi Pasteur, and the US Centers for Disease Control and Prevention; and non-financial support (funds to travel to meeting) from Parexel during the conduct of the study. SRCH reports grants from Bill & Melinda Gates Foundation during the

conduct of the study. HO reports grants from the Japan Agency for Medical Research and Development during the conduct of the study. EAFS reports grants, personal fees, and non-financial support (travel to Investigator meetings and to consultation meetings) from AstraZeneca, Merck, Pfizer, Regeneron, and Roche; personal fees from AbbVie, Alere, and Cidara; non-financial support (travel to meetings) from AbbVie and Novavax; other support fees for being on data and safety monitoring board from AbbVie and GlaxoSmithKline; and grants from Johnson and Johnson and Novavax, outside the submitted work. JAGS reports grants from the Bill & Melinda Gates Foundation, Gavi, The Vaccine Alliance, the UK Medical Research Council, the UK National Institute for Health Research, and the Wellcome Trust, outside the submitted work. L-MY reports grants from Japan Initiative for Global Research Network on Infectious Diseases and Agency for Medical Research and Development during the conduct of the study. HJZ reports grants from the Bill & Melinda Gates Foundation, the South Africa Medical Research Council, and the South Africa National Research Foundation, outside the submitted work. HC reports grants from the Bill & Melinda Gates Foundation, Johns Hopkins University, Sanofi, and WHO; and personal fees from the Bill & Melinda Gates Foundation, Johns Hopkins University, Sanofi, and WHO, during the conduct of the study. HN reports grants from the Bill & Melinda Gates Foundation and personal fees from the Bill & Melinda Gates Foundation during the conduct of the study; and grants from the Foundation for Influenza Epidemiology, Innovative Medicines Initiative, Sanofi, UK National Institute for Health Research, and WHO, and personal fees from AbbVie, Foundation for Influenza Epidemiology, Janssen, Reviral, and Sanofi, outside the submitted work. All other authors declare no competing interests.

Data sharing

The study-level data for all outcomes and detailed analyses are provided in the appendix. In conformity with the GATHER statement, all aggregate data included in this analysis (in an Excel format) will be made publicly available upon publication of the study on Edinburgh DataShare platform.

Acknowledgments

This study was funded by the Bill & Melinda Gates Foundation (OPP 1172551). HN and HC are members of the Respiratory Syncytial Virus Consortium in Europe, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (116019) that receives support from the EU Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. Nagasaki University Vietnam study site data were supported by the Agency for Medical Research and Development (grant no JP19fm0108001; Japan Initiative for Global Research Network on Infectious Diseases). XW and YL were supported by scholarships from the China Scholarship Council during the conduct of this study. The findings and conclusions in this manuscript are those of the authors and do not necessarily represent the official position of the National Institutes of Health, the US Department of Health and Human Services, the Centers for Disease Control and Prevention, Department of Health and Human Services, the Centers for Disease Control and Prevention, or the US Government.

References

- WHO. Child mortality. December, 2018. https://www.who.int/gho/child_health/mortality/causes/en/ (accessed Sept 20, 2019).
- Li Y, Reeves RM, Wang X, et al. Global patterns in monthly activity of influenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus: a systematic analysis. *Lancet Glob Health* 2019; 7: e1031–45.
- Henrickson KJ. Parainfluenza viruses. *Clin Microbiol Rev* 2003; 16: 242–64.
- Ning G, Wang X, Wu D, et al. The etiology of community-acquired pneumonia among children under 5 years of age in mainland China, 2001–2015: a systematic review. *Hum Vaccin Immunother* 2017; 13: 2742–50.
- Lukšić I, Kearns PK, Scott F, Rudan I, Campbell H, Nair H. Viral etiology of hospitalized acute lower respiratory infections in children under 5 years of age—a systematic review and meta-analysis. *Croat Med J* 2013; 54: 122–34.

- 6 Bénét T, Sánchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. *Clin Infect Dis* 2017; **65**: 604–12.
- 7 O'Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. *Lancet* 2019; **394**: 757–79.
- 8 Branche AR, Falsey AR. Parainfluenza virus infection. *Semin Respir Crit Care Med* 2016; **37**: 538–54.
- 9 Bernstein DI, Falloon J, Yi T. A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants. *Vaccine* 2011; **29**: 7042–48.
- 10 Karron RA, Thumar B, Schappell E, et al. Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. *Vaccine* 2012; **30**: 3975–81.
- 11 Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. *Pediatr Infect Dis J* 2012; **31**: 109–14.
- 12 Schmidt AC, Schaap-Nutt A, Bartlett EJ, et al. Progress in the development of human parainfluenza virus vaccines. *Expert Rev Respir Med* 2011; **5**: 515–26.
- 13 Karron RA, San Mateo J, Thumar B, et al. Evaluation of a live-attenuated human parainfluenza type 1 vaccine in adults and children. *J Pediatric Infect Dis Soc* 2015; **4**: e143–46.
- 14 Adderson E, Branum K, Sealy RE, et al. Safety and immunogenicity of an intranasal Sendai virus-based human parainfluenza virus type 1 vaccine in 3- to 6-year-old children. *Clin Vaccine Immunol* 2015; **22**: 298–303.
- 15 Wang X, Li Y, O'Brien KL, et al. Global burden of respiratory infections associated with seasonal influenza in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Health* 2020; **8**: e497–510.
- 16 WHO. Handbook: IMCI integrated management of childhood illness. Geneva: World Health Organization, 2005.
- 17 Wells G, Shea BJ, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analyses. 2011. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (accessed May 11, 2018).
- 18 Stijnen T, Hamza TH, Ozdemir P. Random effects meta-analysis of event outcome in the framework of the generalized linear mixed model with applications in sparse data. *Stat Med* 2010; **29**: 3046–67.
- 19 United Nations, Department of Economic and Social Affairs, Population Division. World population prospects: the 2017 revision. <https://population.un.org/wpp/Publications/> (accessed Feb 1, 2019).
- 20 United Nations Inter-agency group for child mortality estimation. Levels and trends in child mortality report 2018. New York: UNICEF, 2019.
- 21 Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet* 2017; **390**: 946–58.
- 22 UNICEF. Pneumonia care-seeking interactive dashboard. June, 2016. <https://data.unicef.org/resources/pneumonia-care-seeking-interactive-dashboard/> (accessed Oct 1, 2019).
- 23 United Nations Inter-agency group for child mortality estimation. Levels and trends in child mortality report 2015. New York: UNICEF, 2015.
- 24 The World Bank. World Bank country and lending groups. <https://datahelpdesk.worldbank.org/knowledgebase/articles/906519> (accessed Feb 25, 2019).
- 25 Troeger C, Blacker B, Khalil IA, et al. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory infections in 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Infect Dis* 2018; **18**: 1191–210.
- 26 McAllister DA, Liu L, Shi T, et al. Global, regional, and national estimates of pneumonia morbidity and mortality in children younger than 5 years between 2000 and 2015: a systematic analysis. *Lancet Glob Health* 2019; **7**: e47–57.
- 27 Salzberg NT, Sivalogan K, Bassat Q, et al. Mortality surveillance methods to identify and characterize deaths in child health and mortality prevention surveillance network sites. *Clin Infect Dis* 2019; **69** (suppl 4): S262–73.
- 28 R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing, 2018.
- 29 Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw* 2010; **36**: 48.
- 30 Stevens GA, Alkema L, Black RE, et al. Guidelines for accurate and transparent health estimates reporting: the GATHER statement. *Lancet* 2016; **388**: e19–23.
- 31 Wang X, Li Y, Deloria-Knoll M, et al. Global burden of acute lower respiratory infection associated with human metapneumovirus in children under 5 years in 2018: a systematic review and modelling study. *Lancet Glob Health* 2021; **9**: e33–43.
- 32 Simon AK, Hollander GA, McMichael A. Evolution of the immune system in humans from infancy to old age. *Proc Biol Sci* 2015; **282**: 20143085.
- 33 Lee MS, Mendelman PM, Sangli C, Cho I, Mathie SL, August MJ. Half-life of human parainfluenza virus type 3 (hPIV3) maternal antibody and cumulative proportion of hPIV3 infection in young infants. *J Infect Dis* 2001; **183**: 1281–84.
- 34 Feikin DR, Hammitt LL, Murdoch DR, O'Brien KL, Scott JAG. The enduring challenge of determining pneumonia etiology in children: considerations for future research priorities. *Clin Infect Dis* 2017; **64** (suppl 3): S188–96.
- 35 Kuypers J, Wright N, Ferrenberg J, et al. Comparison of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus infections in children. *J Clin Microbiol* 2006; **44**: 2382–88.
- 36 Druce J, Tran T, Kelly H, et al. Laboratory diagnosis and surveillance of human respiratory viruses by PCR in Victoria, Australia, 2002–2003. *J Med Virol* 2005; **75**: 122–29.
- 37 Hammitt LL, Kazungu S, Welch S, et al. Added value of an oropharyngeal swab in detection of viruses in children hospitalized with lower respiratory tract infection. *J Clin Microbiol* 2011; **49**: 2318–20.
- 38 Kim C, Ahmed JA, Eidex RB, et al. Comparison of nasopharyngeal and oropharyngeal swabs for the diagnosis of eight respiratory viruses by real-time reverse transcription-PCR assays. *PLoS One* 2011; **6**: e21610.
- 39 Lambert SB, Whiley DM, O'Neill NT, et al. Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with symptoms for respiratory virus identification using real-time polymerase chain reaction. *Pediatrics* 2008; **122**: e615–20.
- 40 Sung RYT, Chan PKS, Choi KC, et al. Comparative study of nasopharyngeal aspirate and nasal swab specimens for diagnosis of acute viral respiratory infection. *J Clin Microbiol* 2008; **46**: 3073–76.